TrialOncology2020

Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.

Sotaro Sadahiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.